The key finding
A 2024 international consensus project examined over 21,000 published studies to identify the best measurement tools for tracking menopausal hot flashes and night sweats. The team screened 40 different patient questionnaires used in menopause research. Surprisingly, they could recommend validated measurement tools for only three of six core outcomes that matter to women experiencing menopause. No adequately validated questionnaires exist to measure fundamental aspects like hot flash frequency, severity, or satisfaction with treatment — despite these being routinely assessed in clinical trials for decades.
What the study looked like
The COMMA (Core Outcomes in Menopause) consortium brought together 36 researchers and healthcare professionals from 16 countries to systematically review the scientific literature. They conducted a comprehensive search identifying 21,207 publications, from which 119 studies reporting on 40 different patient-reported outcome measures were examined in detail. The team evaluated whether each questionnaire had been properly validated — meaning tested to ensure it actually measures what it claims to measure, produces consistent results, and detects meaningful changes over time. They also assessed whether these tools mapped onto six previously identified core outcomes: frequency, severity, distress/bother/interference, impact on sleep, satisfaction with treatment, and side effects. The consensus process involved multiple rounds of review and voting to reach agreement on final recommendations.
Why researchers think this happened
The gap exists because many measurement tools used in menopause research were developed without rigorous validation processes. Of the 40 questionnaires examined, 36 either didn’t adequately align with what they were supposed to measure or lacked sufficient evidence of their measurement properties — essentially, researchers couldn’t confirm these tools were accurate or reliable. The consortium could only recommend the Hot Flash Related Daily Interference Scale, which measures how much hot flashes interfere with daily life and includes one item about sleep disruption. For side effects, they recommended following standard Good Clinical Practice requirements for reporting adverse events. The absence of validated tools for measuring basic features like frequency and severity reflects a broader problem in medical research: instruments are often adopted and widely used before being properly tested, creating a foundation of potentially unreliable data that accumulates over years.
How to read this carefully
This study doesn’t suggest that hot flashes aren’t real or important — rather, it reveals that our scientific tools for measuring them have been inadequate. The finding comes from expert consensus and systematic review rather than new experimental data. It’s worth noting that this doesn’t invalidate all previous menopause research, but it does raise questions about how reliably past studies have captured outcomes like hot flash frequency or severity. The review focused specifically on published, peer-reviewed measurement properties; some questionnaires might work well in practice but simply lack published validation studies. Additionally, the consortium focused on patient-reported outcomes rather than objective measures, though capturing subjective experiences like “severity” inherently requires self-report. This represents a methodological critique of the field rather than a clinical finding about menopause itself.
What this means for everyday life
If you’re navigating menopause or researching treatment options, this finding suggests taking numerical claims about hot flash reduction with some caution — the tools measuring these outcomes may not have been properly validated. When discussing symptoms with healthcare providers, detailed personal descriptions of your experience may be just as valuable as standardized questionnaire scores. The consortium’s work aims to improve future research by identifying where better measurement tools are needed, which could eventually lead to more reliable comparisons between treatments and better evidence for clinical decision-making. For researchers and clinicians, this study highlights the importance of developing and validating new questionnaires specifically for frequency, severity, and treatment satisfaction. Until those tools exist and are widely adopted, the menopause research community may be building conclusions on shaky measurement foundations — a reminder that even well-established fields of medicine can have surprising gaps in their basic research infrastructure.